Country for PR: United Kingdom
Contributor: PR Newswire Europe
Wednesday, January 19 2022 - 09:00
AsiaNet
XtalPi Partners with Excelra for GOSTAR to Enhance its Intelligent Digital Drug Discovery and Development platform
HYDERABAD, India and SHENZHEN, China, Jan. 19, 2022 /PRNewswire-AsiaNet/--

    Excelra, a leading global Data & Analytics organization, today announced 
the partnership for its Global Online Structure Activity Relationship Database 
(GOSTAR) with XtalPi Inc., an AI-based pharmaceutical biotechnology company 
reinventing the industry's approach to drug research and development with its 
Intelligent Digital Drug Discovery and Development platform.

    Excelra will provide ADMET datasets in the GOSTAR database to XtalPi Inc. 
as part of the partnership. GOSTAR's ADMET data will power XtalPi's predictive 
models. The data helps XtalPi with high precision and predictability to 
confidently tackle clinical failures of new chemical entities. The 
well-annotated, high-quality ADMET datasets of GOSTAR are built with a 
proprietary QMS-ISO certified curation process powered by NLP and human 
intelligence.

    GOSTAR provides comprehensive information encompassing over 8 million 
compounds, manually curated from a variety of sources including patents and 
journal articles. The database contains over 29 million SAR associated data 
points. The well-structured relational database can be utilized for diverse 
applications across various stages of drug discovery and development lifecycle 
and aids in target validation, hit identification, early lead identification, 
and optimization.

    Min Xu, Senior Scientist, Research Manager, XtalPi Inc., said, "In XtalPi 
Inc., we develop advanced AI-based algorithms to tackle the challenges in the 
drug design process. The size and quality of datasets are always a big concern 
for us to build high-accuracy predictive models. That is why we consider GOSTAR 
as a unique and precious resource. It has millions of data points covering 
different compounds' ADMET properties and is also trustful, structured, and 
updated. We highly recommend GOSTAR to whoever is involved in the innovation of 
drug design methodologies."

    Norman Azoulay, Product Leader, Excelra, said, "Artificial Intelligence and 
Machine Learning is bringing a paradigm shift to drug discovery and 
development. This partnership will help train XtalPi's models to accurately 
predict efficacy and safety parameters and to ultimately increase the success 
rate of drug design."

    About XtalPi:

    XtalPi is a pharmaceutical technology company that is reinventing the 
industry's approach to drug research and development with its Intelligent 
Digital Drug Discovery and Development platform. With tightly interwoven 
quantum physics, artificial intelligence, and high-performance cloud computing 
algorithms, XtalPi's platform provides accurate predictions on the 
physiochemical and pharmaceutical properties of small-molecule candidates for 
drug design, solid-form selection, and other critical aspects of drug 
development. XtalPi is dedicated to improving the efficiency, accuracy, and 
success rate of drug research and development, and contributing to a healthier 
society worldwide. To know more, visit http://www.xtalpi.com.

    About Excelra:

    Excelra's data and analytics solutions empower innovation in life sciences 
from molecule to market. The Excelra Edge comes from harmonizing heterogeneous 
data sets, applying innovative bioinformatics know-how and technologies to 
accelerate your drug discovery & development with reliable and result-oriented 
insights. Excelra's GOSTAR is available as an application for users to seek, 
find, and discover compounds. In addition, it is offered via APIs and as a 
downloadable dataset to power in-house libraries and machine learning models.

    For more information about GOSTAR, visit www.gostardb.com  

    Logo: https://mma.prnewswire.com/media/692189/Excelra_Logo.jpg  

    SOURCE - Excelra Knowledge Solutions Pvt Ltd
Translations

Japanese